Comparative Genomics of Two ST 195 Carbapenem-Resistant Acinetobacter baumannii with Different Susceptibility to Polymyxin Revealed Underlying Resistance Mechanism

Frontiers in Microbiology
Soo-Sum LeanKwai-Lin Thong

Abstract

Acinetobacter baumannii is a Gram-negative nosocomial pathogen of importance due to its uncanny ability to acquire resistance to most antimicrobials. These include carbapenems, which are the drugs of choice for treating A. baumannii infections, and polymyxins, the drugs of last resort. Whole genome sequencing was performed on two clinical carbapenem-resistant A. baumannii AC29 and AC30 strains which had an indistinguishable ApaI pulsotype but different susceptibilities to polymyxin. Both genomes consisted of an approximately 3.8 Mbp circular chromosome each and several plasmids. AC29 (susceptible to polymyxin) and AC30 (resistant to polymyxin) belonged to the ST195 lineage and are phylogenetically clustered under the International Clone II (IC-II) group. An AbaR4-type resistance island (RI) interrupted the comM gene in the chromosomes of both strains and contained the bla OXA-23 carbapenemase gene and determinants for tetracycline and streptomycin resistance. AC29 harbored another copy of bla OXA-23 in a large (~74 kb) conjugative plasmid, pAC29b, but this gene was absent in a similar plasmid (pAC30c) found in AC30. A 7 kb Tn1548::armA RI which encodes determinants for aminoglycoside and macrolide resistance, is chromosomally-l...Continue Reading

References

May 1, 1995·Antimicrobial Agents and Chemotherapy·J VilaT Jimenez de Anta
Mar 18, 1996·Biochemical and Biophysical Research Communications·Q B TianY Terawaki
Apr 1, 1996·Clinical Microbiology Reviews·E Bergogne-Bérézin, K J Towner
Jan 20, 2000·Antimicrobial Agents and Chemotherapy·G Bou, J Martínez-Beltrán
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Garnacho-MonteroJ Madrazo-Osuna
Jul 3, 2004·Genome Research·Aaron C E DarlingNicole T Perna
Sep 1, 2004·Cellular and Molecular Life Sciences : CMLS·K Poole
Feb 3, 2005·FEMS Microbiology Letters·Heidi SegalB Gay Elisha
Sep 8, 2005·Journal of Clinical Microbiology·Sergio G BartualFrancisco Rodríguez-Valera
Jan 18, 2006·PLoS Genetics·Pierre-Edouard FournierJean-Michel Claverie
Aug 3, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L Poirel, P Nordmann
Aug 9, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert A Bonomo, Dora Szabo
Feb 28, 2007·The Journal of Antimicrobial Chemotherapy·Jordi VilaJavier Sánchez-Céspedes
Apr 25, 2007·Nucleic Acids Research·Karin LagesenDavid W Ussery
Nov 17, 2007·Nature Reviews. Microbiology·Lenie DijkshoornHarald Seifert
Feb 12, 2008·BMC Genomics·Ramy K AzizOlga Zagnitko
Apr 16, 2008·Nucleic Acids Research·Jason R Grant, Paul Stothard
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa L Maragakis, Trish M Perl
Jun 14, 2008·Cellular Microbiology·Mario JuhasDerek W Hood
Jul 16, 2008·Clinical Microbiology Reviews·David LandmanJohn Quale
Oct 22, 2008·Journal of Bacteriology·Mark D AdamsSteven R Gill
Dec 6, 2008·Folia Histochemica Et Cytobiologica·Piotr WieczorekElzbieta Tryniszewska
Jan 13, 2009·Clinical Microbiology Reviews·George A Jacoby
Jun 3, 2009·Antimicrobial Agents and Chemotherapy·Marco Maria D'AndreaGian Maria Rossolini
Jun 17, 2009·Antimicrobial Agents and Chemotherapy·Mark D AdamsRobert A Bonomo
Dec 10, 2009·The Journal of Antimicrobial Chemotherapy·Paul G HigginsHarald Seifert
Mar 10, 2010·BMC Bioinformatics·Doug HyattLoren J Hauser
Apr 9, 2010·The Journal of Antimicrobial Chemotherapy·Virginia PostRuth M Hall
Aug 10, 2010·Journal of Proteomics·Chika C NwugoLuis A Actis
Aug 18, 2010·Antimicrobial Agents and Chemotherapy·José-Manuel Rodríguez-MartínezPatrice Nordmann
Sep 22, 2010·Antimicrobial Agents and Chemotherapy·Jennifer H MoffattJohn D Boyce
Feb 24, 2011·BMC Genomics·Bart A EijkelkampMelissa H Brown
Mar 15, 2011·Journal of Bacteriology·Chun-Chen ChenShu-Ying Li
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Jennifer H MoffattJohn D Boyce
Apr 19, 2011·International Journal of Antimicrobial Agents·Young Kyoung ParkKwan Soo Ko
Jul 27, 2011·Antimicrobial Agents and Chemotherapy·Guo-Bao TianYohei Doi

❮ Previous
Next ❯

Citations

Jul 21, 2017·The Science of the Total Environment·Jasna HrenovicDijana Skoric
Jul 25, 2017·Journal of Global Antimicrobial Resistance·Ranko LadavacPaul G Higgins
Mar 11, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·William Gustavo LimaMagna Cristina Paiva
May 30, 2019·Antimicrobial Agents and Chemotherapy·Jun-Ichi WachinoYoshichika Arakawa
Jul 23, 2016·Toxins·Laura Fernández-GarcíaMaría Tomas
Jan 5, 2020·Applied Microbiology and Biotechnology·Bora ShinWoojun Park
Feb 23, 2019·Frontiers in Microbiology·Jetsi Mancilla-RojanoAriadnna Cruz-Córdova
Sep 2, 2017·Frontiers in Microbiology·Soo Sum Lean, Chew Chieng Yeo
Apr 13, 2019·International Journal of Molecular Sciences·Anjali Y BhagirathKangmin Duan

❮ Previous
Next ❯

Datasets Mentioned

BETA
CP007535
AB0057

Methods Mentioned

BETA
PCR
3′-phosphotransferase
protein folding

Software Mentioned

Prodigal
Rapid Annotation using Subsystem Technology ( RAST )
RNAmmer
Blast2Go
CGView Server
CVTree
SE
Mauve
PubMLST
tRNAscan

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.